249 studies on GIP agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The exploration of GLP-1 receptor agonists for weight loss in end-stage heart failure patients awaiting heart transplantation carries profound implications for clinical practice and patient access to life-saving proce…
GLP-1 analogues could represent a novel, dual-benefit therapeutic option for patients with psoriasis who also contend with obesity or metabolic syndrome. This research suggests a new avenue for treatment, moving beyon…
If successful, the ARO-INHBE trial could introduce a novel therapeutic mechanism for obesity and type 2 diabetes mellitus (T2DM), potentially offering an alternative or complementary option to existing GLP-1 receptor …
A completed Phase 1 study characterized tirzepatide pharmacokinetics in 32 participants with normal to severe hepatic impairment after a single 5 mg SC dose.
This review provides crucial insights for peptide users and clinicians, clarifying why dual GLP-1R/GIPR agonists like tirzepatide offer superior weight loss and metabolic improvements over single GLP-1RAs like semaglu…
This case underscores the critical importance for clinicians to maintain a high index of suspicion for euglycemic ketoacidosis in patients using tirzepatide, even with normal blood glucose levels. The severe presentat…
The findings from this cost-effectiveness analysis could profoundly impact treatment paradigms for HFpEF patients with obesity in Germany. If tirzepatide demonstrates superior cost-effectiveness, it could become a cor…
Updated 2026 guidelines for obesity and type 2 diabetes mellitus emphasize the crucial role of modern GLP-1 analogues and tirzepatide in comprehensive management.
A randomized trial will compare semaglutide, tirzepatide, and metformin in 66 obese adults to assess their impact on genetic aging over 24 weeks.
If successful, this trial could establish tirzepatide as a novel therapeutic option for Long COVID, addressing a critical gap in treatment. The remote, decentralized design of the study is particularly significant, de…
This real-world study provides crucial validation that tirzepatide effectively promotes meaningful weight loss in both Type 2 Diabetes and non-diabetic obese adults, reinforcing its broad utility. The observed glycemi…
This discovery suggests HDM1005 could represent a significant advancement in treating metabolic disorders, potentially offering enhanced efficacy and a more convenient dosing schedule due to its extended half-life. Fo…
This large-scale observational study is crucial for understanding the real-world comparative effectiveness of tirzepatide against other leading GLP-1RAs in preventing Major Cardiovascular Events in patients with Type …
Incretin-based therapies represent a highly promising and multifaceted approach in hypertension management, uniquely combining significant metabolic and cardiovascular benefits. Their ability to reduce blood pressure,…
Obesity-related HFpEF is a major public health challenge with few targeted treatments, making the potential of Tirzepatide highly significant. If this study successfully identifies the mechanisms by which Tirzepatide …
This study highlights the critical importance of timing when discontinuing GLP-1RA/tirzepatide before pregnancy to mitigate gestational diabetes risk. While longer discontinuation periods appear safe, abrupt cessation…
This case report highlights a critical potential adverse effect of GLP-1 RAs on mood and behavior, particularly in vulnerable populations such as those with pre-existing Major Depressive Disorder. Given that GLP-1 rec…
The potential for a therapeutic strategy that not only achieves significant weight loss but also preserves crucial muscle mass and bone health would be a major advancement in obesity management. Current weight loss ap…
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated …
The review highlights that GLP-1 RAs are highly effective for weight management and glycemic control, offering significant benefits for women with conditions like polycystic ovary syndrome (PCOS) or those at elevated …
This case highlights the critical importance of vigilant monitoring of thyroid function in post-thyroidectomy patients initiating tirzepatide or similar incretin-based medications. The significant weight loss and pote…
This research is significant because it investigates a potential new benefit of tirzepatide beyond weight management and metabolic improvement: reducing breast cancer risk. Given the strong link between obesity and br…
Understanding how GLP-1RAs and GIP/GLP-1-dual agonists affect ocular blood flow and retinal health is critically important given their widespread use in diabetes management. If these medications demonstrate a benefici…
The findings from this study are highly significant for patients managing type 2 diabetes and obesity with Tirzepatide. Knowing that injection site (upper arm, thigh, or abdomen) does not significantly impact drug abs…
This Phase 3 study is critical because it directly compares two of the most promising pharmacological approaches for obesity management, potentially establishing a new standard of care. The results will provide invalu…
This study provides compelling evidence that GLP-1 medicines may offer substantial benefits beyond their primary role in weight loss and metabolic health. The observed improvements in mental health, eating disorder sy…
This study reveals a notable disparity in the utilization of GLP1RAs among individuals with multiple sclerosis who possess cardiometabolic comorbidities that would warrant such treatment. The findings underscore the i…
This study is highly significant because it could establish Tirzepatide as more than just a powerful glucose-lowering agent, potentially offering a crucial benefit in addressing diabetes-related cognitive impairment. …
The successful completion of this Phase 1 safety and tolerability study is a pivotal step for LY3841136 and its potential role in obesity treatment. If LY3841136 proves to be safe and effective in combination with tir…
The findings from this study, once published, will be crucial for understanding the full therapeutic potential of incretin-based therapies beyond current GLP-1 receptor agonists. If the combined GIP and GLP-1 activati…
Given the significant public health burden of Cannabis Use Disorder and the scarcity of effective pharmacological interventions, a successful outcome from this trial could be transformative. Tirzepatide, a dual GLP-1 …
This case report carries significant clinical implications, particularly for endocrinologists and primary care providers prescribing tirzepatide to patients with complex endocrine histories. The finding underscores th…
Understanding the specific metabolic shifts induced by Semaglutide and Tirzepatide is crucial for optimizing obesity treatment strategies. If the study reveals significant, sustained improvements in energy expenditure…